Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.85) per share. This is a 90.51 percent increase over losses of $(8.96) per share from the same period last year.
HTG Provides A Year-End Update On Its Drug Discovery Business And Attends LifeSci Partners 2023 Corporate Access Event
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today provided an